한글목차

라디오세라노스틱스의 동향과 전망

세계 라디오세라스노틱스 시장의 미래는 종양 시장과 비종양 시장에 기회가 있어 유망합니다. 세계 라디오세라스노틱스 시장은 2024년부터 2030년까지 17.3%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 55억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 유병률 증가, 임상시험 수 증가, 정밀의료에 대한 인식 및 채택 증가입니다.

• Lucintel은 루테튬-177 제품의 가용성과 채택이 증가함에 따라 루테튬-177이 방사성 동위원소 카테고리에서 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상하고 있습니다.
• 용도별로는 종양이 여전히 큰 비중을 차지하고 있습니다.
• 지역별로는 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다. 이는 이 지역에서 정밀의료에 대한 관심이 높아지면서 효율적인 이미징 기술 채택이 증가하고 있기 때문입니다.

라디오세라노스틱 시장에서의 전략적 성장 기회

라디오세라노스틱 시장에는 다양한 용도로 다양한 전략적 성장 기회가 존재합니다. 이러한 기회를 활용하면 이 분야를 확장하고 방사성 세라믹 치료의 영향력을 높일 수 있습니다.

• 종양에 대한 적용: 종양학, 특히 치료하기 어려운 암에 대한 방사성의약품의 적용 확대는 의료 미충족 수요를 충족시키고 집중적이고 효율적인 치료를 통해 시장 성장을 가속할 수 있습니다.
• 심장 질환: 심근 관류 영상과 같은 순환기 영역의 라디오세라스노틱스 솔루션 개발은 새로운 시장 영역을 개척하고 심혈관 질환의 진단과 치료를 강화할 것입니다.
• 신경증: 신경학에서는 특히 신경 퇴행성 질환의 영상 진단 및 치료와 관련하여 정확한 진단과 치료를 모두 제공하는 방사성동위원소의 성장 잠재력이 큽니다.
• 감염증: 결핵, 바이러스 감염 등 감염성 질환에 방사성의약품을 확대하여 조기 발견을 돕고 암의 조기 치료를 촉진할 수 있으며, 기존 종양학에 국한되지 않고 적용 범위를 넓힐 수 있습니다.
• 지방의 의료 접근성: 이동형 장치와 원격 의료를 통해 농촌이나 의료 서비스가 부족한 지역에 라디오세라스노틱스 제품을 도입하는 것은 의료 격차를 해소하는 동시에 시장 범위를 확대하는 것입니다.

결론적으로, 이러한 추세는 다양한 의료 전문 분야(특히 엑스레이 촬영)에서 기술 혁신을 촉진하는 전략적 성장 전망을 보여주고 있습니다. 다양한 의료 수요를 충족시킴으로써 이 시장은 지속 가능한 성장을 달성하고 세계 보건에 더 큰 영향을 미칠 수 있습니다.

라디오세라노스틱 시장 활성화 요인 및 과제

다양한 기술적, 경제적, 규제적 요인들이 라디오세라스노틱스 시장에 영향을 미치고 있습니다. 이러한 시장 성장 촉진요인 및 과제를 이해하는 것은 시장을 성공적으로 탐색하고 지속적인 성장을 달성하는 데 필수적입니다.

라디오세라노스틱 시장을 이끄는 요인은 다음과 같습니다.

1. 기술 발전: 방사성의약품의 제조기술, 영상진단법, 표적치료법 등의 혁신으로 효능이 향상되어 시장 확대가 촉진되고 있습니다.

2. 암 발병률 증가: 전 세계 암 환자 증가로 인해 방사성동위원소 같은 표적 치료법이 요구되고 있으며, 이 분야에서 사용되는 방사성동위원소 시장이 확대되고 있습니다.

3. 정부 지원: 규제 우대 및 융자 등을 통해 핵의학 및 정밀 종양학 진흥에 대한 정부 지원이 증가하고 있으며, 방사성 동위원소 산업의 성장을 가속하고 있습니다.

4. 의료의 세계화: 세계 의료 협력으로 인해 특히 개발도상국에서 방사성동위원소 치료에 대한 접근성이 확대되고 있습니다.

5. 개인맞춤형 의료에 대한 환자 수요: 개인맞춤형 저침습 치료에 대한 환자들의 요구가 높아지면서 맞춤형 치료 옵션을 제공하는 라디오세라스노틱스의 채택이 가속화되고 있습니다.

라디오세라노스틱 시장의 과제는 다음과 같습니다.

1. 고가의 제조비용: 방사성 동위원소 제조 및 방사선 종양치료제 개발에는 높은 비용이 소요되기 때문에 구매하기 쉬운 가격과 접근성이 제한되어 시장 성장의 걸림돌로 작용하고 있습니다.

2. 승인 장애: 허가 및 방사성 물질의 안전한 취급에 대한 엄격한 규제 요건은 새로운 치료법의 도입을 지연시킬 수 있습니다.

3. 공급망 문제: 반감기가 짧고 생산시설이 한정되어 있어 공급 부족으로 치료받지 못하는 경우가 발생할 수 있습니다.

결론적으로, 방사성 세라믹 시장은 높은 제조 비용과 규제 장벽이라는 문제에 직면해 있지만, 기술 발전과 개인 맞춤형 의료에 대한 수요 증가에 힘입어 성장하고 있습니다. 시장 참여자들이 지속적인 성장을 달성하고 환자에게 혁신적인 치료법을 제공하기 위해서는 이러한 요인들을 잘 극복하는 것이 필수적입니다.

목차

제1장 주요 요약

제2장 세계의 라디오세라스노틱스 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018년-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 라디오세라스노틱스 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 라디오세라스노틱스 시장 : 방사성 동위 원소별
  • Iodine-131
  • Iodine-123
  • Gallium-68
  • Lutetium-177
  • 18F With Y-90
  • 기타
• 세계의 라디오세라스노틱스 시장 : 접근별
  • 표적 치료
  • 표적 진단
• 세계의 라디오세라스노틱스 시장 : 용도별
  • 종양
  • 종양 이외

제4장 지역별 시장 동향과 예측 분석(2018년-2030년)

• 세계의 라디오세라스노틱스 시장 : 지역별
• 북미의 라디오세라스노틱스 시장
• 유럽의 라디오세라스노틱스 시장
• 아시아태평양의 라디오세라스노틱스 시장
• 기타 지역의 라디오세라스노틱스 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 라디오세라스노틱스 시장 성장 기회 : 방사성 동위 원소별
  • 세계의 라디오세라스노틱스 시장 성장 기회 : 접근별
  • 세계의 라디오세라스노틱스 시장 성장 기회 : 용도별
  • 세계의 라디오세라스노틱스 시장 성장 기회 : 지역별
• 세계 라디오세라스노틱스 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 라디오세라스노틱스 시장 생산능력 확대
  • 세계 라디오세라스노틱스 시장의 인수합병(M&A) 및 합작투자
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

영문목차

Radiotheranostic Trends and Forecast

The future of the global radiotheranostic market looks promising with opportunities in the oncology and non-oncology markets. The global radiotheranostic market is expected to reach an estimated $5.5 billion by 2030 with a CAGR of 17.3% from 2024 to 2030. The major drivers for this market are the increasing prevalence of cancer, the rising number of clinical trials, and the growing awareness and adoption of precision medicines.

• Lucintel forecasts that, within the radioisotope category, lutetium-177 is expected to witness the highest growth over the forecast period due to the increasing availability and adoption of lu-177 products.
• Within the application category, oncology will remain the larger segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the increasing adoption of efficient imaging technologies along with a growing inclination towards precision medicine in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radiotheranostic Market

Emerging trends in the radiotheranostics market are reshaping its future applications and dynamics:

• Precision Oncology: One of these trends is precision oncology, which uses radiotheranostics to target cancerous cells specifically, thus sparing healthy tissues from harm. It has become a cornerstone in modern cancer therapy, as it leads to better patient outcomes with fewer side effects.
• Globalization of Radioisotope Supply: This globalization ensures that the supply chains of radioisotopes are broader, leading to the availability of radiotheranostics therapies from any part of the world. Such efforts help mitigate potential shortages through the diversification of sources, ensuring consistent access to treatments globally.
• Integration with Digital Health: The introduction of AI and telemedicine among digital health technologies into radiotheranostics allows for better diagnosis and treatment planning. These innovations facilitate real-time monitoring and more accurate dosimetry, resulting in improved therapeutic outcomes.
• Expansion Beyond Oncology: The use of radiotheranostics has extended beyond oncology into cardiology, neurology, and infectious diseases. This creates new opportunities and expands the reach of these interventions.
• Patient-Centric Care Models: We are seeing the introduction of patient-centered care models based on personalized treatment plans and a multispecialty approach in the radiotheranostics field. These models are raising patient satisfaction levels and improving adherence to therapeutic protocols, which in turn enhances therapeutic outcomes.

In conclusion, these trends are revolutionizing radiotheranostics and making it a cornerstone of personalized medicine, gradually penetrating diverse fields of medicine.

Recent Developments in the Radiotheranostic Market

The radiotheranostics market is rapidly evolving, with several key developments shaping its growth and impact. These advancements have increased the effectiveness of treatment and expanded access to radiotheranostics therapies.

• Novel Radiation Theragnostic Agents: The development of new radiation theragnostic agents, specifically for prostate and neuroendocrine tumors, has resulted in more precise treatment and better outcomes for patients.
• Advanced Manufacturing Techniques: Advanced radioisotope production techniques have increased the availability of critical isotopes, such as Lutetium-177 and Gallium-68, which are used for cancer diagnosis, reducing costs and widening access to these therapies.
• Regulatory Approvals: Simplified regulatory proceedings in key markets have facilitated faster approval of radiotherapeutics, enabling swift access to novel treatments for patients.
• Strategic Collaborations: Strategic alliances between pharmaceutical companies, research institutions, and healthcare service providers aim to foster innovation while enhancing the development and delivery of radioactive therapeutics.
• Global Market Expansion: Growing investment in nuclear medicine infrastructure globally, coupled with the adoption of therapies in emerging markets, has necessitated global growth in radiotheranostics.

In conclusion, these key developments are strongly impacting the radiotheranostics market by fueling innovation, increasing access, and improving patient outcomes. As the market continues to grow, these changes will be instrumental in shaping its future.

Strategic Growth Opportunities for Radiotheranostic Market

A variety of strategic growth opportunities exist within multiple applications across the radiotheranostics market. Tapping into these opportunities can expand the sector and increase the influence of radiotheranostics therapies.

• Oncology Applications: Expanding radiotherapeutic applications for oncology, especially for hard-to-treat cancers, can address unmet medical needs and stimulate market growth through focused and efficient treatment.
• Cardiology: The development of radiotheranostics solutions in cardiology, such as for myocardial perfusion imaging, will open up new market areas and enhance the diagnosis and treatment of cardiovascular conditions.
• Neurology: In neurology, there is great potential for the growth of radiotheranostics, particularly with respect to imaging and treating neurodegenerative diseases, providing both accurate diagnostics and therapy.
• Infectious Diseases: Expanding radiotheranostics into infectious diseases, such as tuberculosis and viral infections, will assist in early detection and promote early cancer treatment, widening the scope beyond traditional oncology applications.
• Rural Healthcare Access: The use of mobile units or telemedicine to bring radiotheranostics into rural and underserved areas would reduce healthcare disparities while expanding the market reach.

In conclusion, these trends present strategic growth prospects that are driving innovation within various medical specialties, particularly radiography. By addressing diverse healthcare needs, the market can achieve sustainable growth and have a broader impact on global health.

Radiotheranostic Market Driver and Challenges

Various technological, economic, and regulatory factors affect the radiotheranostics market. Understanding these drivers and challenges is essential for navigating the market successfully and achieving sustainable growth.

The factors responsible for driving the radiotheranostic market include:

1. Technological Advancements: Innovations in radiation therapeutics production techniques, imaging methods, and targeted therapies have enhanced their effectiveness, stimulating market expansion.

2. Rising Cancer Incidence: The global increase in cancer cases demands more target-oriented therapies like radiotherapy, resulting in larger markets for radioisotopes used in this area.

3. Government Support: Increasing government assistance for the promotion of nuclear medicine and precision oncology through regulatory incentives and financing is boosting the growth of the radiotheranostics industry.

4. Globalization of Healthcare: Global healthcare collaborations have opened up access to radiotheranostics therapies, especially in developing nations.

5. Patient Demand for Personalized Medicine: Growing patient demand for personalized, minimally invasive treatments is driving the adoption of radiotheranostics, which offer tailored therapeutic options.

Challenges in the radiotheranostic market include:

1. Expensive Production Costs: The high cost of producing radioisotopes and developing radiotheranostics agents can limit affordability and access, posing a challenge to market growth.

2. Obstacles in Approvals: Stringent regulatory requirements for approval and the safe handling of radioactive materials can delay the introduction of new therapies.

3. Supply Chain Challenges: These include short half-life periods and limited production facilities, creating the potential for shortages and leading to treatment unavailability.

In conclusion, the radiotheranostics market is driven by technological advancements and the rising demand for personalized medicine, while facing challenges such as high production costs and regulatory hurdles. Successfully navigating these factors is essential for market players to achieve sustainable growth and deliver innovative treatments to patients.

List of Radiotheranostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiotheranostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiotheranostic companies profiled in this report include-

• Novartis
• Bayer
• Progenics Pharmaceuticals
• Telix Pharmaceuticals Limited
• ITM Radiopharma
• Life Molecular Imaging
• RadioMedix

Radiotheranostic by Segment

The study includes a forecast for the global radiotheranostic by radioisotope, approach, application, and region.

Radiotheranostic Market by Radioisotope [Analysis by Value from 2018 to 2030]:

• Iodine-131
• Iodine-123
• Gallium-68
• Lutetium-177
• 18F With Y-90
• Others

Radiotheranostic Market by Approach [Analysis by Value from 2018 to 2030]:

• Targeted Therapeutic
• Targeted Diagnostic

Radiotheranostic Market by Application [Analysis by Value from 2018 to 2030]:

• Oncology
• Non-Oncology

Radiotheranostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radiotheranostic Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments by major radiotheranostics producers in key regions: the USA, China, India, Japan, and Germany:

• United States: The FDA has approved several radiotheranostics therapies for prostate cancer and neuroendocrine tumors, among others. This has been made possible by increasing funding in research and academic-industry partnerships that foster the development of next-generation radiotheranostics.
• China: China's investment in its nuclear medicine infrastructure includes the domestic production of radioisotopes. Recently, the country has established centers for radiotheranostics therapies through collaborations with global firms, meeting the rising demand for precise oncology care delivery.
• Germany: Institutions like the Deutsches Krebsforschungszentrum (German Cancer Research Center) have taken leadership roles in conducting clinical trials for new agents used in radiotheranostics. The country is also improving its regulatory framework to expedite patient access to modern treatments.
• India: Government-driven initiatives aimed at enhancing nuclear medicine capabilities are positioning India as a key player in the growing radiotheranostics domain. Recent developments include affordable radiotheranostics solutions and collaborations with overseas partners to boost technical know-how.
• Japan: Japan has seen progress in radioisotope production and distribution, among other developments, all aimed at integrating radiotheranostics into personalized medicine. Government support for research and the development of novel radiotheranostics agents is driving market growth, particularly in oncology.

Features of the Global Radiotheranostic Market

Market Size Estimates: Radiotheranostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiotheranostic market size by radioisotope, approach, application, and region in terms of value ($B).

Regional Analysis: Radiotheranostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotope, approaches, applications, and regions for the radiotheranostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiotheranostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radiotheranostic market by radioisotope (iodine-131, iodine-123, gallium-68, lutetium-177, 18F with Y-90, and others), approach (targeted therapeutic and targeted diagnostic), application (oncology and non-oncology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiotheranostic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radiotheranostic Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radiotheranostic Market by Radioisotope
  • 3.3.1: Iodine-131
  • 3.3.2: Iodine-123
  • 3.3.3: Gallium-68
  • 3.3.4: Lutetium-177
  • 3.3.5: 18F with Y-90
  • 3.3.6: Others
• 3.4: Global Radiotheranostic Market by Approach
  • 3.4.1: Targeted Therapeutic
  • 3.4.2: Targeted Diagnostic
• 3.5: Global Radiotheranostic Market by Application
  • 3.5.1: Oncology
  • 3.5.2: Non-oncology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radiotheranostic Market by Region
• 4.2: North American Radiotheranostic Market
  • 4.2.1: North American Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.2.2: North American Market by Application: Oncology and Non-oncology
• 4.3: European Radiotheranostic Market
  • 4.3.1: European Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.3.2: European Market by Application: Oncology and Non-oncology
• 4.4: APAC Radiotheranostic Market
  • 4.4.1: APAC Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.4.2: APAC Market by Application: Oncology and Non-oncology
• 4.5: ROW Radiotheranostic Market
  • 4.5.1: ROW Market by Radioisotope: Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, and Others
  • 4.5.2: ROW Market by Application: Oncology and Non-oncology

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radiotheranostic Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Radiotheranostic Market by Approach
  • 6.1.3: Growth Opportunities for the Global Radiotheranostic Market by Application
  • 6.1.4: Growth Opportunities for the Global Radiotheranostic Market by Region
• 6.2: Emerging Trends in the Global Radiotheranostic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radiotheranostic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiotheranostic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Bayer
• 7.3: Progenics Pharmaceuticals
• 7.4: Telix Pharmaceuticals Limited
• 7.5: ITM Radiopharma
• 7.6: Life Molecular Imaging
• 7.7: RadioMedix